Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.85B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 0.95M
Average 1.18M
VERA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Vera Therapeutics, Inc.NASDAQ: VERA
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents broadly unchanged from a year ago
Cash & equivalents stood at $48.88M at the end of Q2 FY2026, down 0.5% from a year earlier and down 57.3% from the prior quarter. Over 3 fiscal years it compounded at +101.3% a year.
Context
- Cash & equivalents amounted to 9.2% of total assets at the end of Q2 FY2026, up 0.7 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -0.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 354.73M USD
- Year-over-year change
- +282.9%
- 4-year CAGR
- +45.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 354.73M | +282.9% |
| FY2024 | 2024-12-31 | 92.65M | +102.8% |
| FY2023 | 2023-12-31 | 45.68M | +5.1% |
| FY2022 | 2022-12-31 | 43.46M | -45.5% |
| FY2021 | 2021-12-31 | 79.67M | — |
Cash & Equivalents vs competitors
How VERA compares with its peers on the latest reported figures
- VERA's Jun 2026 cash & equivalents of $48.88M is the 7th highest of the 10 companies compared; the peer median is $63.71M.
- Its year-over-year change of -0.5% is the 5th highest of 10, against a peer median of -5.6%.
- Cash & equivalents amounts to 9.2% of total assets for VERA, versus a peer median of 12.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $298.49M | +9.9% | +103.8% | 74.6% | |
| Mar 2026 | $248.47M | +151.9% | +49.5% | 75.4% | |
| Jun 2026 | $238.03M | +43.6% | +3.9% | 64.2% | |
| Jun 2026 | $110.55M | +735.2% | +49.3% | 9.1% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $63.71M | -58.0% | +51.8% | 11.4% |
| Mar 2026 | $53.1M | -11.6% | -11.0% | 10.9% | |
| Jun 2026 | $48.88M | -0.5% | +101.3% | 9.2% | |
| Jun 2026 | $34.12M | -53.3% | -7.2% | 7.0% | |
| Mar 2026 | $32.19M | -43.4% | +48.7% | 12.5% | |
| Mar 2026 | $28.66M | -5.6% | -23.9% | 14.4% | |
| Peer median (excluding VERA) | $63.71M | -5.6% | +48.7% | 12.5% | |
Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 79.67M | 43.46M | 45.68M | 92.65M | 354.73M |
| Short-term Investments | 0 | 71.19M | 115.04M | 548.21M | 359.86M |
| Net Receivables | 0 | 0 | 0 | 3.77M | 3.29M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 480K | 719K | 3.22M | 913K | 2.54M |
| Total Current Assets | 82.54M | 125.7M | 172.02M | 651.22M | 728.88M |
| Property, Plant & Equipment (Net) | 0 | 5.22M | 3.04M | 4.33M | 1.92M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 867K | 58K | 11K | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 344K | 455K | 471K | 131K | 3.93M |
| Total Non-current Assets | 1.21M | 5.74M | 3.52M | 4.46M | 5.85M |
| Total Assets | 83.75M | 131.44M | 175.55M | 655.68M | 734.73M |
| Account Payables | 1.39M | 11.99M | 11.12M | 7.67M | 21.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 377K | 0 | 4.82M | 0 | 1.37M |
| Total Current Liabilities | 7.69M | 25.6M | 22.3M | 25.37M | 53.46M |
| Long-term Debt | 4.92M | 24.81M | 49.88M | 50.69M | 74.84M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.54M | 286K | 286K | 0 | 0 |
| Total Non-current Liabilities | 6.47M | 28.93M | 51.56M | 53.16M | 76.76M |
| Total Liabilities | 14.16M | 54.53M | 73.86M | 78.53M | 130.21M |
| Common Stock | 21K | 28K | 44K | 64K | 71K |
| Retained Earnings | (124.06M) | (213.11M) | (309.1M) | (461.25M) | (760.87M) |
| Accumulated OCI | (0) | (224K) | 251K | 393K | 786K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 69.59M | 76.91M | 101.69M | 577.16M | 604.52M |
| Total Debt | 4.92M | 31.29M | 53.71M | 54.64M | 77.31M |
| Net Debt | (74.75M) | (12.17M) | 8.03M | (38.01M) | (277.42M) |
Vera Therapeutics, Inc.
NASDAQ:VERA
Intrinsic Alpha fair value
Locked
Current Price
$25.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.